Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2CNS 2Sarcoma 1NET 1

Conditions

Ovarian Neoplasms 86Breast Neoplasms 68Triple Negative Breast Neoplasms 32Prostatic Neoplasms 32Fallopian Tube Neoplasms 25Neoplasms 23Neoplasm Metastasis 21Pancreatic Neoplasms 18Endometrial Neoplasms 18Small Cell Lung Carcinoma 13Carcinoma, Ovarian Epithelial 11Carcinoma, Non-Small-Cell Lung 10Stomach Neoplasms 9Sarcoma 9Recurrence 9Lung Neoplasms 9Fanconi Anemia, Complementation Group D1 9Squamous Cell Carcinoma of Head and Neck 8Glioma 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Glioblastoma 7Colorectal Neoplasms 6Metastatic Castration-resistant Prostate Cancer 5Lymphoma, Non-Hodgkin 5Cholangiocarcinoma 5Carcinoma, Renal Cell 5Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Solid Tumors 4Osteosarcoma 4

Interventions

3-Iodobenzylguanidine 8Temozolomide 6lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 4anlotinib 4Specimen Handling 4Everolimus 4Radiotherapy 3Phenoxybenzamine 3Magnetic Resonance Spectroscopy 3Doxorubicin 36-fluorodopamine 3olaparib 2cabozantinib 2belzutifan 2Nivolumab 2Ifosfamide 2Fluorodeoxyglucose F18 2Filgrastim 2Doxazosin 2Dexmedetomidine 2Capecitabine 2Biopsy 2Axitinib 23-fluorobenzylguanidine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2veliparib 1vatalanib 1vandetanib 1tipifarnib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Pheochromocytoma × olaparib × Clear all
NCT06607692 2026-06-04

LUPARPED

Fundación de investigación HM

Phase 1/2 Recruiting
25 enrolled
CNSEndocrineNETSarcoma

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT04394858 2026-05-13

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
46 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡